Formulation and Specifications: Tablets: 200 mg
Indications: Treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer.
Key points for rational dosing:
1. Administered on an empty stomach, no genetic testing is required prior to dosing. If the disease is stable in the long term, such drugs are not required.
2. Suspension and/or dose reduction of sorafenib may be required in the presence of suspected adverse drug reactions.
3. The most common adverse reactions are diarrhea, malaise, hair loss, infection, skin reactions on hands and feet, and rash.
4. Contraindicated in patients with severe hypersensitivity to sorafenib or any of the inactive ingredients of this product.
5. Caution is required when co-applied with drugs metabolized/cleared by the UGT1A1 pathway; caution is required when co-applied with docetaxel; co-application with CYP3A4 inducers can result in reduced drug concentrations of sorafenib; co-application with neomycin can result in reduced exposure to sorafenib.